[A23-57] Riociguat (pulmonary arterial hypertension in children and adolescents) – Benefit assessment according to §35a Social Code Book V
Last updated 02.10.2023
Project no.: A23-57
Commission: Commission awarded on 26.06.2023 by the Federal Joint Committee (G-BA).
Report type: Dossier assessment
Status: Commission completed
Department/Division: Drug Assessment
Topic: Heart and circulation
Treatment of pulmonary arterial hypertension in paediatric patients aged less than 18 years of age and body weight ≥ 50 kg with WHO Functional Class II to III
Added benefit not proven
After completion of the assessment by IQWiG the Federal Joint Committee (G-BA) conducts a commenting procedure. This may provide supplementary information and as a result lead to a modified benefit assessment. Further information and the decision on the early benefit assessment can be found on the relevant page of the G-BA website.